Wednesday, August 26, 2026

OpenAI Targets $100B Annual Ad Revenue by 2030 Through Trade Desk, Criteo Partnerships

OpenAI expects ad revenue to reach $100B annually by 2030 as it begins showing ads in ChatGPT and partners with The Trade Desk and Criteo for ad sales. The advertising push comes as the Microsoft-financed company seeks revenue diversification while competing against Alphabet and Meta in AI commercialization.

LM Salvado
LM Salvado

April 17, 2026

OpenAI Targets $100B Annual Ad Revenue by 2030 Through Trade Desk, Criteo Partnerships
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

OpenAI expects ad revenue to rise to $100B annually by 2030 as it begins showing advertisements in ChatGPT.1 The company is exploring a partnership with The Trade Desk and has partnered with Criteo for ad sales.1

The advertising expansion marks a strategic shift for the Microsoft-financed AI company.1 OpenAI competes directly with Alphabet and Meta Platforms, both of which generate substantial revenue from advertising businesses.1

Beyond advertising, OpenAI is expanding enterprise partnerships. Novo Nordisk has partnered with OpenAI for AI-driven drug discovery, demonstrating commercial applications outside the ad market.1

The dual revenue strategy—advertising and enterprise partnerships—reduces OpenAI's dependency on Microsoft Corporation financing.1 Microsoft has been the primary financial backer, but diversified revenue streams position OpenAI for competitive sustainability in the AI commercialization race.1

The $100B annual ad revenue target would place OpenAI among major digital advertising players. For context, Alphabet and Meta have established ad businesses generating hundreds of billions combined, creating a competitive benchmark for OpenAI's ambitions.1

The Trade Desk partnership could provide OpenAI with programmatic advertising infrastructure, while Criteo brings performance marketing capabilities. Both partnerships suggest OpenAI is building a comprehensive ad technology stack rather than a single-channel approach.

The timeline to 2030 gives OpenAI four years to scale ad operations while maintaining its research mission. The company faces the challenge of balancing user experience in ChatGPT with advertising integration, a tension that established platforms like Google and Facebook have navigated over decades.

Enterprise partnerships like Novo Nordisk demonstrate OpenAI's API and custom AI applications can generate revenue independent of advertising. This two-track strategy mirrors successful tech companies that combine consumer advertising with enterprise software sales.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Network, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com